Sex-specific difference of in-hospital mortality from COVID-19 in South Korea

Ae-Young Her1☯, Youngjune Bhak2☯, Eun Jung Jun3, Song Lin Yuan3,4, Scot Garg5, Semin Lee2, Jong Bhak2, Eun-Seok Shin3*

1 Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, South Korea, 2 Department of Biomedical Engineering, College of Information-Bio Convergence Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan, South Korea, 3 Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea, 4 Department of Cardiology, Dong-A University Hospital, Busan, South Korea, 5 East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, United Kingdom

☯ These authors contributed equally to this work.
* sesim1989@gmail.com

Abstract

We sought to assess the impact of sex on in-hospital mortality of patients with COVID-19 infection in South Korea. The study recruited 5,628 prospective consecutive patients who were hospitalized in South Korea with COVID-19 infection, and enrolled in the Korea Centers for Disease Control and Prevention (KCDC) dataset between January 20, 2020, and April 30, 2020. The primary endpoint was in-hospital death from COVID-19. The cohort comprised of 3,308 women (59%) and 2,320 men (41%). In-hospital death was significantly lower in women than men (3.5% vs. 5.5%, hazard ratio (HR): 0.61; 95% confidence interval (CI): 0.47 to 0.79, p < 0.001). Results were consistent after multivariable regression (HR: 0.59; 95% CI: 0.41 to 0.85, p = 0.023) and propensity score matching (HR: 0.51; 95% CI: 0.30 to 0.86, p = 0.012). In South Korea, women had a significantly lower risk of in-hospital death amongst those patients hospitalized with COVID-19 infection.

Introduction

Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China in December 2019, it has rapidly spread around the world [1–3]. As of June 11, 2021, the World Health Organisation (WHO) reported a total of 174,789,927 COVID-19 cases globally, with an average mortality of 2.2%. Experience from past outbreaks highlights the importance of incorporating a sex analysis into the preparedness and response efforts to improve the effectiveness of health interventions, and promote sex and health equity goals [4]. Interestingly, a recent analysis of COVID-19 data from 188 countries has shown sex-specific mortality differences with higher death rates in men compared with women, although the underlying mechanisms are unclear [5]. However, these findings are not consistent in all countries, and sex-specific morbidity and mortality vary among different countries. This would imply that there are geographic, genetic, cultural and/or sex-specific differences that may influence the spread of COVID-19 and subsequent mortality.
Therefore, the aim of this study was to assess the impact of sex on in-hospital mortality amongst patients hospitalized with COVID-19 infection in South Korea.

Materials and methods

Study population and endpoint

This prospective consecutive cohort study using the Korea Centers for Disease Control and Prevention (KCDC) dataset enrolled patients with a history of hospitalization for COVID-19 between January 20, 2020, and April 30, 2020, in South Korea. All patients with COVID-19 were diagnosed and treated according to the guidelines published by the KCDC (http://www.cdc.go.kr) [6]. The reverse transcription polymerase chain reaction test was used for detecting COVID-19, and nasal and pharyngeal swab specimens were collected from patients. A person who tested positive was confirmed to be infected with COVID-19 regardless of the presence of any clinical symptoms. The primary endpoint was in-hospital death during the hospital stay. All the patients analyzed either died in hospital or were discharged home despite the limitations that we could not acquire the information for in-hospital mortality due to other causes except COVID-19 or underlying diseases [6].

Statistical analysis

An extended description of the statistical analysis is presented in the Online Appendix. Cumulative event rates were calculated based on Kaplan-Meier censoring estimates, and comparison of clinical outcomes between women and men was performed with the log-rank test. Because differences in baseline characteristics could significantly affect outcomes, sensitivity analyses were performed to adjust for confounders as much as possible. First, a multivariable Cox regression model was used. Covariates in the multivariable model were selected if they were significantly different between women and men or had predictive values. Cox proportional hazard models for primary end point satisfied the proportional hazards assumption. Second, the logistic regression method was used in a propensity score matching. Propensity score matching yielded 621 patients in women and 621 control subjects in men. Balance between the 2 groups after propensity score matching was assessed by calculating standardized mean differences. The standardized mean differences after propensity score matching were within 0.1 across all matched covariates, demonstrating successful balance achievement between comparative groups (S1 Table in S1 File). To identify independent predictors of in-hospital death, we used a multivariable Cox proportional hazard model. C-statistics with 95% confidence intervals (CIs) were calculated to validate the discriminant function of the model. In addition, comparisons of the primary end point between women and men according to the exploratory subgroups of interest were followed, and the interaction between treatment effect and these covariates was assessed with a Cox regression model. Statistical analyses were performed using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria). All probability values were 2-sided, and p value < 0.05 was considered statistically significant. The data can be accessed for analysis once approved by Korea Centers for Disease Control and Prevention (https://is.kdca.go.kr/).

Ethical approval

This study was approved by the ethics committee of the KCDC and written informed consent was exempted because of the de-identified retrospective nature of the publicly available data.
Results

Baseline clinical characteristics of the patients are shown in Table 1. A total of 5,628 patients with confirmed COVID-19 infection were included in the KCDC dataset during the pandemic period. Confirmed cases were more frequent in women (n = 3,308, 59%) than in men (n = 2,320, 41%). The age distribution between the sexes was significantly different (Table 1 and Fig 1). The proportion of middle-aged (40 to 59 years old; 37.6% vs. 27.7%, p < 0.001) and very-elderly (>80 years old) patients (6.7% vs. 4.5%, p < 0.001) was higher in women compared with men. The percentage of underweight (6.7% vs. 4.7%, p = 0.004) and overweight (18.6% vs. 30.9%, p < 0.001) patients was significantly higher in women and men, respectively. The prevalences of systolic blood pressure (SBP) ≥130 mmHg (49.6% vs. 63.0%, p < 0.001) and diastolic blood pressure (DBP) ≥80 mmHg (58.7% vs. 65.6%, p < 0.001) were significantly higher in men. The prevalence of diabetes mellitus (DM) (11.1% vs. 14.0%, p < 0.001), chronic obstructive pulmonary disease (COPD) (0.5% vs. 1.1%, p = 0.006), and chronic liver disease (1.1% vs. 2.2%, p = 0.002) were lower in women compared with men. Dementia was more frequent (4.9% vs. 3.2%, p = 0.002) in women compared with men.

Body temperature at initial diagnosis (37.0 ± 0.5˚C vs. 36.9 ± 0.6˚C, p < 0.001) was higher in women. Among accompanying symptoms, the prevalence of cough (43.0% vs. 39.6%, p = 0.011), sputum (31.1% vs. 25.6%, p < 0.001), sore throat (17.9% vs. 12.5%, p < 0.001), myalgia (18.1% vs. 14.1%, p < 0.001), headache (20.2% vs. 12.9%, p < 0.001), and nausea/vomiting (5.3% vs. 2.9%, p < 0.001) were higher in women compared with men. The white blood cell (WBC) count (6,051 ± 2,681 μL vs. 6,243 ± 3,033 μL, p = 0.035), hemoglobin (12.7 ± 1.4 g/dL vs. 14.2 ± 1.9 g/dL, p < 0.001), and hematocrit (37.8 ± 4.2% vs. 41.5 ± 5.3%, p < 0.001) were lower in women. Lymphocyte (30.1 ± 11.1% vs. 27.6 ± 12.3%, p < 0.001) and platelet (244,638 ± 81,462 μL vs. 224,320 ± 83,692 μL, p < 0.001) counts were higher in women compared with men. The median admission duration was 24 days (Interquartile range: 18 to 32 days).

The prevalence of COVID-19 infection and in-hospital mortality according to sex and age is presented in Fig 1. Above 40 years of age the prevalence of the disease was more common in women compared with men, and whilst in-hospital mortality increased with age for both sexes, it was always higher in men compared with the same aged women over 40. A comparison of in-hospital outcomes between women and men is presented in Fig 2. The cumulative incidences of in-hospital death were higher in men. The risk of death was significantly lower in women than in men (3.5% vs. 5.5%; hazard ratio (HR): 0.61; 95% CI: 0.47 to 0.79; p < 0.001, log-rank p < 0.001) (Fig 3). Sensitivity analyses using multivariable Cox regression (HR: 0.59; 95% CI: 0.41 to 0.85; p = 0.023) and propensity score matching (HR: 0.51; 95% CI: 0.30 to 0.86), p = 0.012) showed consistently lower risk of death in women compared with men (Table 2). In Table 2, there were no significant differences of clinical outcomes between women and men except in-hospital death.

Multivariable Cox proportional hazard models identified independent predictors of the primary end point (Table 3). In women, age, body mass index (BMI), cardiovascular disease, chronic kidney disease, malignancy, dyspnea, lymphocyte count, and platelet count were independent predictors of in-hospital death. In men, age, heart rate, malignancy, autoimmune disease, dementia, fever, sputum, dyspnea, headache, and lymphocyte were independent predictors of in-hospital death. Fig 4 presents the prognostic impact of women among the various subgroups. The significantly lower risk of death in women than in men was consistent across all subgroups except some subgroups with significant interaction p values. In Fig 5, women showed a significantly lower risk of in-hospital death than men, which was consistently observed after thorough sensitivity analyses for adjustment of baseline differences.
Table 1. Baseline clinical characteristics and outcomes.

| Variables                  | Total (n = 5,628) | Women (n = 3,308) | Men (n = 2,320) | p-value |
|----------------------------|-------------------|-------------------|-----------------|---------|
| Age, years                 |                   |                   |                 | <0.001  |
| 0–9                        | 66 (1.2)          | 29 (0.9)          | 37 (1.6)        | 0.014   |
| 10–19                      | 206 (3.7)         | 98 (3.0)          | 108 (4.7)       | <0.001  |
| 20–29                      | 1119 (19.9)       | 569 (17.2)        | 550 (23.7)      | <0.001  |
| 30–39                      | 564 (10.0)        | 295 (8.9)         | 269 (11.6)      | <0.001  |
| 40–49                      | 742 (13.2)        | 376 (11.6)        | 366 (16.0)      | <0.001  |
| 50–59                      | 1,146 (20.4)      | 557 (16.9)        | 589 (25.3)      | <0.001  |
| ≥60                        | 916 (16.3)        | 539 (16.3)        | 377 (16.2)      | 0.965   |
| BMI, kg/m²                 |                   |                   |                 | <0.001  |
| <18.5 (underweight)        | 260 (5.9)         | 173 (6.7)         | 87 (4.7)        | 0.004   |
| 18.5–24.9 (normal)         | 2,906 (65.7)      | 1,805 (70.4)      | 1,101 (59.1)    | <0.001  |
| 25.0–29.9 (overweight)     | 1,052 (23.8)      | 476 (18.6)        | 576 (30.9)      | <0.001  |
| ≥30.0 (obesity)            | 208 (4.7)         | 109 (4.3)         | 99 (5.3)        | 0.100   |
| SBP, mmHg                  |                   |                   |                 | <0.001  |
| <130                       | 2,462 (44.9)      | 1,629 (50.4)      | 833 (37.0)      | <0.001  |
| ≥130                       | 3,024 (55.1)      | 1,603 (49.6)      | 1,421 (63.0)    | <0.001  |
| DBP, mmHg                  |                   |                   |                 | <0.001  |
| <80                        | 2,113 (38.5)      | 1,335 (41.3)      | 778 (34.5)      | <0.001  |
| ≥80                        | 3,373 (61.5)      | 1,897 (58.7)      | 1,476 (65.5)    | <0.001  |
| Heart rate, beats/min      | 86 ± 15           | 85 ± 15           | 86 ± 15         | 0.152   |
| Body temperature, °C       | 36.9 ± 0.6        | 37.0 ± 0.5        | 36.9 ± 0.6      | <0.001  |
| Combined comorbidity, n (%)|                   |                   |                 |         |
| Hypertension               | 1,201 (21.4)      | 695 (21.0)        | 506 (21.8)      | 0.455   |
| Diabetes mellitus          | 691 (12.3)        | 366 (11.1)        | 325 (14.0)      | <0.001  |
| Cardiovascular disease     | 224 (4.0)         | 121 (3.7)         | 103 (4.5)       | 0.135   |
| Bronchial asthma           | 128 (2.3)         | 82 (2.5)          | 46 (2.0)        | 0.222   |
| COPD                       | 40 (0.7)          | 15 (0.5)          | 25 (1.1)        | 0.006   |
| Chronic kidney disease     | 55 (1.0)          | 29 (0.9)          | 26 (1.1)        | 0.357   |
| Malignancy                 | 145 (2.6)         | 96 (2.9)          | 49 (2.1)        | 0.066   |
| Chronic liver disease      | 83 (1.6)          | 35 (1.1)          | 48 (2.2)        | 0.002   |
| Autoimmune disease         | 38 (0.7)          | 26 (0.8)          | 12 (0.5)        | 0.217   |
| Dementia                   | 224 (4.2)         | 153 (4.9)         | 71 (3.2)        | 0.002   |
| Accompanying symptom, n (%)|                   |                   |                 |         |
| Fever                      | 1,305 (23.2)      | 784 (23.7)        | 521 (22.5)      | 0.286   |
| Cough                      | 2,341 (41.6)      | 1,423 (43.0)      | 918 (39.6)      | 0.011   |
| Sputum                     | 1,619 (28.8)      | 1,027 (31.1)      | 592 (25.6)      | <0.001  |
| Sore throat                | 881 (15.7)        | 591 (17.9)        | 290 (12.5)      | <0.001  |
| Rhinorrhea                 | 621 (11.0)        | 382 (11.6)        | 239 (10.3)      | 0.145   |
| Myalgia                    | 926 (16.5)        | 600 (18.1)        | 326 (14.1)      | <0.001  |
| Fatigue                    | 234 (4.2)         | 134 (4.1)         | 100 (4.3)       | 0.626   |
| Dyspnea                    | 666 (11.8)        | 403 (12.2)        | 263 (11.4)      | 0.340   |
| Headache                   | 967 (17.2)        | 668 (20.2)        | 299 (12.9)      | <0.001  |
| Altered mental status      | 35 (0.6)          | 19 (0.6)          | 16 (0.7)        | 0.586   |
| Nausea/Vomiting            | 244 (4.3)         | 176 (5.3)         | 68 (2.9)        | <0.001  |
| Diarrhea                   | 518 (9.2)         | 317 (9.6)         | 201 (8.7)       | 0.245   |

(Continued)
| Variables                  | Total (n = 5,628) | Women (n = 3,308) | Men (n = 2,320) | p-value |
|----------------------------|-------------------|-------------------|-----------------|---------|
| Laboratory data            |                   |                   |                 |         |
| WBC, μL                    | 6,126 ± 2,824     | 6,051 ± 2,681     | 6,243 ± 3,033   | 0.035   |
| Lymphocyte, %              | 29.1 ± 11.7       | 30.1 ± 11.1       | 27.6 ± 12.3     | <0.001  |
| Platelet, x10³/μL          | 236.7 ± 82.9      | 244.6 ± 81.4      | 224.3 ± 83.6    | <0.001  |
| Hemoglobin, g/dL           | 13.3 ± 1.8        | 12.7 ± 1.4        | 14.2 ± 1.9      | <0.001  |
| Hematocrit, %              | 39.2 ± 5.0        | 37.8 ± 4.2        | 41.3 ± 5.3      | <0.001  |
| Disease severity           |                   |                   |                 | <0.001  |
| No limit of activity       | 4,455 (79.5)      | 2,648 (80.5)      | 1,807 (78.2)    | 0.041   |
| Limit of activity but no O₂| 330 (5.9)         | 212 (6.4)         | 118 (5.1)       | 0.037   |
| O₂ with nasal prong        | 469 (8.4)         | 268 (8.1)         | 201 (8.7)       | 0.458   |
| O₂ with facial mask        | 43 (0.8)          | 20 (0.6)          | 23 (1.0)        | 0.102   |
| Non-invasive ventilation   | 33 (0.6)          | 16 (0.6)          | 17 (0.7)        | 0.229   |
| Invasive ventilation       | 19 (0.3)          | 9 (0.3)           | 10 (0.4)        | 0.312   |
| Multi-organ failure/ECMO   | 11 (0.2)          | 4 (0.1)           | 7 (0.3)         | 0.131   |
| Death                      | 241 (4.3)         | 114 (3.5)         | 127 (5.5)       | <0.001  |
| Admission site             |                   |                   |                 | <0.001  |
| Intensive care unit        | 189 (3.4)         | 74 (2.2)          | 115 (5.0)       |         |
| General ward               | 5,410 (96.6)      | 3,216 (97.8)      | 2,194 (95.0)    |         |
| Relief of isolation, n (%) | 5,387 (95.7)      | 3,194 (96.5)      | 2,193 (95.5)    | <0.001  |
| Duration of isolation, days| 24.0 (18.0–32.0)  | 24.0 (18.0–32.0)  | 24.0 (18.0–31.0)| 0.244   |

Data are mean ± SD or number (percentage) or median (quartile 1–3). BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; COPD = chronic obstructive pulmonary disease; WBC = whole blood count; ECMO = extracorporeal membrane oxygenation.

https://doi.org/10.1371/journal.pone.0262861.t001

**Fig 1.** The prevalence of COVID-19 infection and in-hospital mortality according to sex and age. Data are percentage of in-hospital death. The bright and dark red boxes represent the number of discharged and in-hospital deaths in women. The bright and dark blue boxes represent the number of discharged and in-hospital deaths in men.

https://doi.org/10.1371/journal.pone.0262861.g001
Discussion

The main findings of this study were as follows. First, women had a significantly lower risk of in-hospital death compared to men, which was maintained even after adjustment of baseline differences. Second, in the multivariable Cox proportional hazard model, women were
independently associated with a decreased risk of in-hospital death. Third, the significantly lower risk of in-hospital death in women compared with men was consistently observed in various subgroups.

The first reports of COVID-19 suggested a sex imbalance with regards to detected cases and case fatality rate, with several subsequent studies suggesting that more men develop serious symptoms and have a higher mortality compared with women, potentially due to sex-based immunological or gendered differences [7–9]. However, sex-based disaggregated data of mortality from COVID-19 are still not available from all countries and a thorough analysis of sex-specific differences of mortality is currently lacking [4, 10].

Table 2. Comparison of clinical outcomes between women and men.

|                      | Women (n = 3,308) | Men (n = 2,320) | Unadjusted HR (95% CI) | p-value | Multivariable-adjusted HR (95% CI) | p-value | Propensity score matched HR (95% CI) | p-value |
|----------------------|------------------|----------------|------------------------|---------|----------------------------------|---------|-------------------------------------|---------|
| No limit of activity | 2,648 (80.5)     | 1,807 (78.2)   | 0.99 (0.93–1.05)       | 0.779   | 1.10 (0.99–1.22)                 | 0.077   | 1.09 (0.96–1.24)                    | 0.180   |
| Limit of activity but no O₂ | 212 (6.4) | 118 (5.1) | 1.20 (0.96–1.50) | 0.118 | 1.10 (0.74–1.64) | 0.625 | 1.57 (0.95–2.61) | 0.079 |
| O₂ with nasal prong | 268 (8.1)       | 201 (8.7)      | 0.87 (0.72–1.04)       | 0.130   | 0.87 (0.67–1.13)                 | 0.306   | 0.98 (0.72–1.34)                    | 0.895   |
| O₂ with facial mask | 20 (0.6)        | 23 (1.0)       | 0.55 (0.30–1.01)       | 0.053   | 0.73 (0.30–1.81)                 | 0.497   | 0.46 (0.12–1.77)                    | 0.259   |
| Non-invasive ventilation | 16 (0.6) | 17 (0.7) | 0.70 (0.34–1.41) | 0.317 | 1.66 (0.60–4.60) | 0.334 | 1.73 (0.41–7.25) | 0.453 |
| Invasive ventilation | 9 (0.3)         | 10 (0.4)       | 0.80 (0.30–2.15)       | 0.655   | 0.38 (0.08–1.80)                 | 0.224   | 0.15 (0.02–1.25)                    | 0.079   |
| Multi-organ failure/ECMO | 4 (0.1) | 7 (0.3) | 0.27 (0.07–1.03) | 0.056 | Inf (0.00–Inf) | 0.841 | 2.14 (0.19–23.64) | 0.534 |
| Death                 | 114 (3.5)       | 127 (5.5)      | 0.61 (0.47–0.79)       | <0.001  | 0.59 (0.41–0.85)                 | 0.023   | 0.51 (0.30–0.86)                    | 0.012   |

Data are number (percentage). CI = confidence interval; HR = hazard ratio; ECMO = extracorporeal membrane oxygenation.

Table 3. Predictors of in-hospital mortality by logistic regression analysis in women and men.

| Variable                   | Women                   | Men                     |
|----------------------------|-------------------------|-------------------------|
|                           | HR (95% CI) p-value     | HR (95% CI) p-value     |
| Age, per 10 years         | 2.64 (1.77–7.71) 0.006  | 2.08 (1.50–2.90) <0.001 |
| BMI, per categories       | 0.83 (0.58–1.18) <0.001 | 1.28 (0.93–1.76) 0.132 |
| Heart rate                | 1.02 (1.00–1.04) 0.080  | 1.02 (1.00–1.03) 0.039 |
| Cardiovascular disease    | 3.31 (1.42–7.71) 0.006  | 0.51 (0.22–1.21) 0.126 |
| Bronchial asthma          | 2.88 (0.90–9.22) 0.075  | 0.49 (0.09–2.79) 0.422 |
| Chronic kidney disease    | 3.98 (1.32–12.0) 0.014 | 0.63 (0.12–3.34) 0.587 |
| Malignancy                | 3.46 (1.06–11.3) 0.040  | 2.79 (1.14–6.83) 0.025 |
| Autoimmune disease        | 0 (0–Inf) 0.996         | 16.16 (1.84–141.80) 0.012 |
| Dementia                  | 1.97 (0.89–4.36) 0.942  | 4.57 (1.98–10.57) <0.001 |
| Fever                     | 0.84 (0.34–3.11) 0.714  | 4.18 (1.96–8.89) <0.001 |
| Sputum                    | 1.18 (0.53–2.64) 0.681  | 2.50 (1.17–5.34) 0.018 |
| Dyspnea                   | 4.28 (2.05–8.91) <0.001 | 2.12 (1.12–4.02) 0.022 |
| Headache                  | 0.29 (0.07–1.24) 0.094  | 0.20 (0.04–0.90) 0.036 |
| Altered mental status     | 1.24 (0.18–8.32) 0.827  | 3.29 (0.93–11.55) 0.638 |
| Lymphocyte, %             | 0.93 (0.89–0.96) <0.001 | 0.94 (0.90–0.98) 0.004 |
| Platelet, x10⁴/μL         | 0.95 (0.91–1.00) 0.035  | 0.97 (0.93–1.00) 0.087 |
| Hematocrit, %             | 0.93 (0.80–1.09) 0.388  | 0.92 (0.83–1.02) 0.841 |

HR = hazard ratio; CI = confidence interval; BMI = body mass index, less than 18.5 as 1, 18.5 to 22.9 as 2, 23.0 to 24.9 as 3, 25.0 to 29.9 as 4, more than or equal to 30 as 5.

https://doi.org/10.1371/journal.pone.0262861.t002

https://doi.org/10.1371/journal.pone.0262861.t003
Fig 4. Subgroup analysis for sex-specific differences of in-hospital death by binary regression hazard ratio analysis in crude population. The results of exploratory subgroup analysis should be interpreted in the context of a significant interaction p value, and not the individual comparison in each subgroup, due to multiple testing issues. CI = confidence interval; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure.

| Variable                        | Women (n = 3,308) | Men (n = 2,320) | Hazard ratio (95% CI) | Interaction p value |
|---------------------------------|-------------------|-----------------|-----------------------|---------------------|
| Age                             |                   |                 |                       |                     |
| <60                             | 6/2,236           | 13/1,607        |                       | 0.33 (0.12-0.86)    | 0.214               |
| ≥60                             | 108/1,072         | 114/713         |                       | 0.62 (0.48-0.81)    |                     |
| BMI                             |                   |                 |                       |                     |
| <18.5                           | 11/173            | 5/87            |                       | 1.15 (0.4-3.31)     | 0.146               |
| 18.5-24.9                       | 29/1,805          | 37/1,101        |                       | 0.5 (0.3-0.81)      | 0.368               |
| 25.0-29.9                       | 11/476            | 28/576          |                       | 0.43 (0.21-0.87)    | 0.417               |
| ≥30.0                           | 3/109             | 2/99            |                       | 1.34 (0.22-8.04)    | 0.343               |
| SBP                             |                   |                 |                       |                     |
| <130                            | 46/1,629          | 40/833          |                       | 0.58 (0.38-0.89)    | 0.616               |
| ≥130                            | 60/1,603          | 77/1,421        |                       | 0.67 (0.48-0.95)    |                     |
| DBP                             |                   |                 |                       |                     |
| <80                             | 53/1,335          | 51/778          |                       | 0.63 (0.43-0.92)    | 0.852               |
| ≥80                             | 53/1,897          | 66/1,476        |                       | 0.60 (0.42-0.87)    |                     |
| Cardiovascular disease          |                   |                 |                       |                     |
| Yes                             | 19/121            | 20/103          |                       | 0.77 (0.41-1.45)    | 0.457               |
| No                              | 95/3,179          | 107/2,206       |                       | 0.61 (0.46-0.8)     |                     |
| Bronchial asthma                |                   |                 |                       |                     |
| Yes                             | 9/82              | 4/46            |                       | 1.13 (0.34-3.68)    | 0.293               |
| No                              | 105/3,226         | 123/2,271       |                       | 0.59 (0.46-0.77)    |                     |
| Chronic kidney disease          |                   |                 |                       |                     |
| Yes                             | 11/29             | 5/26            |                       | 2.34 (0.80-6.85)    | 0.01                |
| No                              | 103/3,279         | 122/2,291       |                       | 0.58 (0.45-0.75)    |                     |
| Malignancy                      |                   |                 |                       |                     |
| Yes                             | 8/96              | 14/49           |                       | 0.29 (0.12-0.69)    | 0.056               |
| No                              | 106/3,211         | 113/2,268       |                       | 0.65 (0.5-0.85)     |                     |
| Dementia                        |                   |                 |                       |                     |
| Yes                             | 46/153            | 29/71           |                       | 0.65 (0.41-1.04)    | 0.333               |
| No                              | 68/2,949          | 98/2,216        |                       | 0.49 (0.36-0.67)    |                     |
| Fever                           |                   |                 |                       |                     |
| Yes                             | 34/784            | 59/521          |                       | 0.37 (0.24-0.56)    | 0.002               |
| No                              | 80/2,523          | 68/1,796        |                       | 0.84 (0.6-1.15)     |                     |
| Cough                           |                   |                 |                       |                     |
| Yes                             | 37/1,423          | 44/918          |                       | 0.55 (0.35-0.85)    | 0.449               |
| No                              | 77/1,884          | 83/1,339        |                       | 0.67 (0.49-0.91)    |                     |
| Sputum                          |                   |                 |                       |                     |
| Yes                             | 28/1,027          | 44/592          |                       | 0.36 (0.23-0.58)    | 0.009               |
| No                              | 86/2,280          | 83/1,725        |                       | 0.77 (0.57-1.05)    |                     |
| Myalgia                         |                   |                 |                       |                     |
| Yes                             | 6/600             | 15/326          |                       | 0.21 (0.08-0.54)    | 0.016               |
| No                              | 108/2,707         | 112/1,991       |                       | 0.70 (0.54-0.92)    |                     |
| Fatigue                         |                   |                 |                       |                     |
| Yes                             | 3/134             | 14/100          |                       | 0.14 (0.04-0.50)    | 0.017               |
| No                              | 111/3,173         | 113/2,217       |                       | 0.68 (0.52-0.88)    |                     |
| Dyspnea                         |                   |                 |                       |                     |
| Yes                             | 47/403            | 66/263          |                       | 0.43 (0.3-0.63)     | 0.027               |
| No                              | 67/2,904          | 61/2,054        |                       | 0.78 (0.55-1.10)    |                     |
| Headache                        |                   |                 |                       |                     |
| Yes                             | 4/668             | 9/299           |                       | 0.19 (0.06-0.61)    | 0.037               |
| No                              | 110/2,639         | 118/2,018       |                       | 0.70 (0.54-0.91)    |                     |
| Altered mental status           |                   |                 |                       |                     |
| Yes                             | 10/19             | 13/16           |                       | 0.50 (0.22-1.13)    | 0.331               |
| No                              | 104/3,288         | 114/2,301       |                       | 0.63 (0.48-0.82)    |                     |

https://doi.org/10.1371/journal.pone.0262861.g004
Recently the Global Health 50/50 research initiative presented an interesting overview of sex-based disaggregated data from countries worldwide, clearly demonstrating similar numbers of cases among men and women, but with an increased case fatality rate in men (https://globalhealth5050.org/covid19/) [11]. Previous Korean national data during the initial period of COVID-19 infection showed that the case fatality rate and mortality were higher in men than women [12]. Similarly, our study showed that the cumulative incidence of in-hospital mortality from COVID-19 was higher in men compared with women (3.5% vs. 5.5%, p < 0.001); our data show that 60% more hospitalized men died from COVID-19 than women. The higher mortality for men from COVID-19 does not directly imply that they are more vulnerable to the disease than women. For example, men had a higher prevalence of DM, cardiovascular disease, COPD, and chronic liver disease compared with women in this study, and these sex-specific differences could be contributing factors for the sex-biased mortality from COVID-19. Our study, however, confirms the robustness of these sex-specific differences with the consistently lower rates of in-hospital mortality from COVID-19 in women, observed even after multivariable adjustment and propensity score matching analysis (3.5% in women vs. 6.8% in men, p = 0.010). These significant differences in the men to women COVID-19 case fatality ratio can be observed between European and Asian countries, and these case fatality rates are relatively homogenous and range between 1.7–1.8 in men compared to women [11, 13–15].

Previously, a report including 38 countries provided sex-disaggregated data for a men bias in COVID-19 mortality such as higher 1.7 times of men case mortality ratio (women mortality 4.4 (95% CI 3.4–5.5) vs. men mortality 7.3 (95% CI 5.4–9.2) [13], which is consistent with our result of higher 1.6 times of men mortality than women (S1 Fig). This means that a consistent biological phenomenon may be operating, independent of country-specific demographics and national strategies.

**Adjusted HR (95% CI) for in-hospital death**

| Unadjusted         | 0.61 (0.47-0.79) |
|--------------------|------------------|
| Multivariable-adjusted | 0.59 (0.41-0.85) |
| PS-matched         | 0.51 (0.30-0.86) |

**Favors Women**

**Favors Men**

*Fig 5. Exploratory subgroup analysis for in-hospital death.* Women showed a significantly lower risk of in-hospital death than men, which was consistently observed after adjustment of baseline differences. In the multivariable Cox proportional hazard model, women were independently associated with a decreased risk of in-hospital death.

PS = propensity score.

https://doi.org/10.1371/journal.pone.0262861.g005
Although the mechanisms and pathogenesis underlying these sex-specific differences are not fully understood, several studies suggested that the difference in immune system function between women and men could be an important determinant. Women are known to show a robust immune response to pathogens which could help them to better regulate viral load and viral clearance compared with men [16]. Since many immune genes are present on the X chromosome, the XX and XY genetic constitutions may contribute to COVID-19 severity and mortality [17]. Other differences including steroid hormone and sex organs such as testis and ovaries could also play an important role in pathogenesis. Estrogen in women can have immune-enhancing effects, while testosterone can have immune-suppressive effects [18–20]. In addition, several clinical trials highlight the relevance of sex differences in the renin angiotensin aldosterone system (RAAS), and there is increasing evidence that sex and sex hormones affect many components of circulating as well as tissue-based RAAS, including angiotensin converting enzyme (ACE) 2 and cellular serine protease TMPRSS2 [11, 21, 22]. The latter has been suggested to account for the higher mortality seen in men affected by COVID-19, and is of particular interest in the treatment of COVID-19, as a protein that primes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells [23, 24].

Lastly, when considering sex-specific differences in mortality, we should also consider how sex interacts with gender to influence vulnerability. Gender differences include differences in social and economic consequences as a result of the pandemic, including risk of domestic violence, economic and job insecurity, and increased domestic workload [4, 11, 25]. Contrary to other reports on COVID-19, we showed that the number of women infected with COVID-19 was 1.4 fold higher than men (59% vs. 41%), despite a women to men ratio of 50% in the general population. In South Korea, specific religious groups were associated with the largest number of COVID-19 infected patients [26], and the predominance of women in these religious groups could have influenced the female bias in Korean COVID-19 outbreak. Additionally, the occupational hazards of a crowded workplace, such as a call center (affected patients were predominantly women) could be a risk factor for COVID-19 infection in South Korea [27]. Finally, womens role as caregivers within the health system and at home may place them at increased risk of infection, and women are more likely to care for children or other family members who are ill [4]. Therefore, these social and cultural factors could have led to sex-specific differences in COVID-19, and more research is needed to understand how sex and gender are causing differential clinical outcomes and effects related to COVID-19 between women and men.

There are some limitations to our study that need consideration. First, this study has an innate limitation regarding its observational nature with registry data. For instance, men were more needed oxygen with activity and more went straight to the ICU compared to women, and these baseline differences could significantly affect outcomes. However, with the extensive sensitivity analyses, the confounders were adjusted to minimize the bias from different baseline characteristics. Second, this study used the national database of KCDC, in which the individual detailed characteristics relevant to sex and gender including socioeconomic status, smoking history, immunological condition, and unreported co-morbid conditions were not recorded. Third, we performed comparative analyses using surveillance data, which could not show information on precise clinical management, medicine, and sufficient laboratory and imaging data such as markers of disease severity at admission and chest computed tomography images. Finally, our results are not applicable to all countries and cases of COVID-19 owing to our analysis being confined to South Korea.

In conclusion, women had a significantly lower risk of in-hospital death amongst those patients hospitalized with COVID-19 infection in South Korea.
Supporting information

S1 Fig. Men predominance in COVID-19 mortality (deaths divided by confirmed cases) in worldwide and South Korea. A men to women mortality ratio of 1 reflects sex balance, the blue bars reflect men predominance. The worldwide data were obtained from (12) Scully EP et al. Nat Rev Immunol. 2020;20(7):442–7.

(TIF)

S1 File.

(DOCX)

Acknowledgments

We acknowledge all the health-care workers involved in the diagnosis and treatment of COVID-19 patients in South Korea. We thank the Korea Centers for Disease Control and Prevention Agency, National Medical Center and the Health Information Manager in hospitals for their effort in collecting the medical records.

Author Contributions

Conceptualization: Ae-Young Her, Eun-Seok Shin.

Data curation: Ae-Young Her, Youngjune Bhak, Eun Jung Jun, Song Lin Yuan, Semin Lee, Jong Bhak, Eun-Seok Shin.

Formal analysis: Ae-Young Her, Youngjune Bhak, Eun Jung Jun, Song Lin Yuan, Semin Lee, Jong Bhak, Eun-Seok Shin.

Funding acquisition: Jong Bhak, Eun-Seok Shin.

Methodology: Youngjune Bhak.

Supervision: Eun-Seok Shin.

Validation: Ae-Young Her, Scot Garg, Semin Lee, Jong Bhak, Eun-Seok Shin.

Writing – original draft: Ae-Young Her, Youngjune Bhak.

Writing – review & editing: Scot Garg.

References

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579:265–269. https://doi.org/10.1038/s41586-020-2008-3 PMID: 32015508

2. Li Q, Guan X, Wu P, Wang X, Zhou Y, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382:1199–1207. https://doi.org/10.1056/NEJMoa2001316 PMID: 31995857

3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323:2052–2059. https://doi.org/10.1001/jama.2020.6775 PMID: 32320003

4. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. Lancet. 2020; 395:846–848. https://doi.org/10.1016/S0140-6736(20)30526-2 PMID: 32151325

5. Pradhana A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020; 11:53. https://doi.org/10.1186/s13293-020-00330-7 PMID: 32848238

6. Her AY, Bhak Y, Jun EJ, Yuan SL, Garg S, Lee S, et al. A Clinical Risk Score to Predict In-hospital Mortality from COVID-19 in South Korea. J Korean Med Sci. 2021; 36:e108. https://doi.org/10.3346/jkms.2021.36.e108 PMID: 33876588
7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 PMID: 32007143
8. Di Stadio A, Ricci G, Greco A, de Vincentis M, Ralli M. Mortality rate and gender differences in COVID-19 patients dying in Italy: A comparison with other countries. Eur Rev Med Pharmacol Sci. 2020; 24:4066–4067. https://doi.org/10.26355/eurrev_202004_20980 PMID: 32374012
9. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020; 8:152. https://doi.org/10.3389/fpubh.2020.00152 PMID: 32411652
10. Bhopal R. Covid-19 worldwide: we need precise data by age group and sex urgently. BMJ. 2020; 369:m1366. https://doi.org/10.1136/bmj.m1366 PMID: 32245830
11. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020; 11:29. https://doi.org/10.1186/s13293-020-00304-9 PMID: 32450906
12. Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020. J Korean Med Sci. 2020; 35:e132. https://doi.org/10.3346/jkms.2020.35.e132 PMID: 32233161
13. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020; 20:442–447. https://doi.org/10.1038/s41577-020-0348-8 PMID: 32528136
14. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020; 71:799–806. https://doi.org/10.1093/cid/ciaa351 PMID: 32271376
15. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020; 369:m1443. https://doi.org/10.1136/bmj.m1443 PMID: 32317267
16. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016; 16:626–638. https://doi.org/10.1038/nri.2016.90 PMID: 27546235
17. Koopman P. Sex determination: a tale of two Sox genes. Trends Genet. 2005; 21:367–370. https://doi.org/10.1016/j.tig.2005.05.006 PMID: 15949865
18. Taneja V. Sex Hormones Determine Immune Response. Front Immunol. 2018; 9:1931. https://doi.org/10.3389/fimmu.2018.01931 PMID: 30210492
19. Zhao S, Zhu W, Xue S, Han D. Testicular defense systems: immune privilege and innate immunity. Cell Mol Immunol. 2014; 11:428–437. https://doi.org/10.1038/cmi.2014.38 PMID: 24954222
20. Dejucq N, Jégu B. Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev. 2001; 65:208–231. https://doi.org/10.1128/MMBR.65.2.208-231.2001 PMID: 11381100
21. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the Angiotensin converting enzyme 2-Angiotensin (1–7)-MAS receptor axis: fetal programming, sex differences, and intracellular pathways. Front Endocrinol. 2014; 4:201.
22. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002; 53:672–677. https://doi.org/10.1016/s0008-6363(01)00479-5 PMID: 11861038
23. Clinckemalie L, Spans L, Dubois V, Laurent M, Helsen C, Joniau S, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013; 27:2028–2040. https://doi.org/10.1210/me.2013-1098 PMID: 24109594
24. Hoffmann M, Kleine-Web er H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181:271–280. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651
25. Heise L, Greene ME, Opper N, Stavropoulou M, Harper C, Nascimento M, et al. Gender inequality and restrictive gender norms: framing the challenges to health. Lancet. 2019; 393:2440–2454. https://doi.org/10.1016/S0140-6736(19)30652-X PMID: 31155275
26. Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020; 35:e112. https://doi.org/10.3346/jkms.2020.35.e112 PMID: 32174069
27. Park SY, Kim YM, Yi S, Lee S, Na BJ, Kim CB, et al. Coronavirus Disease Outbreak in Call Center, South Korea. Emerg Infect Dis. 2020; 26:1666–1670. https://doi.org/10.3201/eid2608.201274 PMID: 32324530